Combining immune therapy with targeted radiation for liver cancer treatment
Official title: Local Tumoral Delivered Immune Checkpoint Blockades Immunotherapy and Radioembolization Combination Therapy
Funded at Northwestern University at Chicago · NIH-10915561 · Data updated 2026-11-12
This study is testing a new way to treat liver cancer by combining a special type of immune therapy with targeted radiation to help make the treatment more effective, and it's for patients who are looking for better options to fight their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $338,934 |
| NIH project number | 5R01CA282664-02 |
| Project ID | NIH-10915561 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who are not eligible for surgical resection or transplantation.
✕Less likely to help
Patients with other types of cancer or those who have already undergone extensive treatment for HCC may not benefit from this research.
What this research studies
This research investigates a new treatment approach for hepatocellular carcinoma (HCC), a common and deadly liver cancer. It combines immune checkpoint blockade (ICB) immunotherapy with 90Y-radioembolization, a targeted radiation therapy that delivers high doses of radiation directly to the tumor while sparing healthy tissue. The goal is to enhance the effectiveness of the immune therapy by using the radiation to induce cell death in the tumor, potentially leading to better patient outcomes. Patients will be monitored closely to assess the treatment's impact on tumor response and overall health.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with liver cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous clinical trials have shown promise in combining immunotherapy with targeted therapies, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Kim, Dong-Hyun — Northwestern University at Chicago
- Study coordinator: Kim, Dong-Hyun
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.